Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies.

In the following sections, we analyze data and trends in securities class actions across all industries and in the life sciences industry in particular. We then highlight important 2024 decisions issued by federal courts in securities cases brought against life sciences companies and their officers.

Read the full report here.

Michael Siekman, Huiya Wu, Allegra Padula, and Riley Wyberg will present their data-driven analyses of trends in BPCIA litigation and relevant takeaways.

With 10 years of litigation since the first BPCIA complaint on NEUPOGEN (filgrastim) was filed in 2014, trends are becoming apparent that should cause all biopharma companies to reassess how they protect biologics and plan for biosimilar launch.

Webinar Highlights:

• • Patents Being Asserted: Learn which types of patents are being asserted to block biosimilar competition, how that has changed over time, differences for protein and antibody products, when those patents are being filed during drug development, and differences among Reference Product Sponsors.
  • Trends in BPCIA Litigation: Learn how often and how much of aBLAs are being produced during the Patent Dance, which Biosimilar Manufacturers are producing them, how much the parties dance and who is engaging in the Patent Dance, when cases are settling, and how many asserted patents are carrying through to a final judgment.
  • Real-World Insights: We will share practical recommendations for biologics and biosimilars companies based upon on our analysis and our experience with the BPCIA.

Please RSVP to confirm your attendance.

Arman Oruc, Andy Lacy, Sarah Jordan, and Stephen Mavroghenis are excited to invite you to join Goodwin for an in-person, engaging discussion on antitrust in life sciences transactions, navigating global merger control investigations and what to do when your deal hits a regulatory brick wall. We’ll cover the latest trends in early-stage deals, strategies for surviving antitrust scrutiny, and stories from deals that didn’t make it through. Special guests Abbas Kazimi, Chief Executive Officer at Nimbus Therapeutics, Jana Gold, Principal at JanaGold Law (former General Counsel of Maze Therapeutics), and Jeff Stoll, Partner, Deal Advisory & Strategy at KPMG, will join to speak on the fireside chat and panel discussion. Don’t miss this chance to gain practical insights, ask the tough questions, and discuss what’s to come over cocktails!

CLE credit will be offered for CA, NY, NJ, and PA (pending approval).

Please RSVP here to join us.